There are several reports demonstrating tumor growth suppression in vivo when applying TRAIL as mono therapy or in combination with other drugs, and recombinant TRAIL or corresponding agonistic antibodies are in clinical evaluation for various cancer types [14]. The gene discussed is TNFSF10; the disease is neoplasm.